24 September 2019

Up to 24% of patients with acute coronary syndromes present with ST-segment elevation myocardial infarction (STEMI) but show complete resolution of ST-segment elevation and symptoms before revascularization. Current guidelines do not clearly state whether these patients with transient STEMI should be treated with a STEMI-like or non–ST-segment elevation acute coronary syndrome–like intervention strategy.

Niels van Royen, theme Vascular damage, and colleagues, found out that patients with transient STEMI have limited infarction and well-preserved myocardial function in general, and delayed or immediate revascularization has no effect on functional outcome and clinical events up to 1 year. They have published their findings in JACC: Cardiovascular Interventions. 

Methods
In this multicenter trial, 142 patients with transient STEMI were randomized 1:1 to either delayed or immediate coronary intervention. Cardiac magnetic resonance imaging was performed at 4 days and at 4-month follow-up to assess infarct size and myocardial function. Clinical follow-up was performed at 4 and 12 months.

Results
In the delayed (22.7 h) and the immediate (0.4 h) invasive groups, final infarct size as a percentage of the left ventricle was very small (0.4% [interquartile range: 0.0% to 2.5%] vs. 0.4% [interquartile range: 0.0% to 3.5%]; p = 0.79), and left ventricular function was good (mean ejection fraction 59.3 ± 6.5% vs. 59.9 ± 5.4%; p = 0.63). In addition, the overall occurrence of major adverse cardiac events, consisting of death, recurrent infarction, and target lesion revascularization, up to 1 year was low and not different between both groups (5.7% vs. 4.4%, respectively; p = 1.00).


Related news items


In order to maximize quality of life in pediatric psoriasis reaching for clear skin is necessary

12 December 2019

In JAMA Dermatology, Bruins et al showed that greatest improvement in quality of life was achieved with 90% improvement of the Psoriasis Area and Severity Index (PASI) and 90% decrease of affected body surface area in a large cohort of children with psoriasis.

read more

Bart-Jan Kullberg appointed as Chair of Health Council

12 December 2019

As of 1 January 2020, Bart-Jan Kullberg has been appointed as the Chairperson of the Health Council of the Netherlands.

read more

Jelle Barentsz's trilogy of educational papers in European Urology

12 December 2019

Recently, a trilogy of educational papers by our full professor Jelle Barentsz has been published in European Urology. The publications address what urologists need to know about prostate-MRI.

read more

Mohrmann Stipend for Bakker and Peters

12 December 2019

Tuesday 10 December, Esmée Bakker and Yonne Peters were awarded a Christine Mohrmann stipend. The grant – 5000 euros each – gives them an opportunity to spend time at another university, preferably one abroad.

read more

ERC Consolidator Grant for Bousema and Sechopoulos

12 December 2019

Teun Bousema and Ioannis Sechopoulos each receive an ERC Consolidator Grant of around two million euros. This European research subsidy will enable them to carry out research for the next five years.

read more

New insights into the initiation of T cell responses in the spleen

11 December 2019

Carl Figdor and colleagues, theme Cancer development and immune defense, provide insights into the initiation of T cell responses in the spleen and their consequences for T cell differentiation. They have published their results in Proceedings of the National Academy of Sciences USA.

read more